Elron Ventures (CE) Quote - ELRNF | ADVFN

S&P ASX All Technology

US Dollar vs AUD

Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

Get Started

Home
Investing
Stocks
USA
USOTC
Elron Ventures Ltd (CE) (ELRNF) Share Price

Elron Ventures Ltd (CE) (ELRNF)

0.92

0.00

(0.00%)

Closed 24 November 8:00AM

Delayed by 15 minutes

Professional-Grade Tools, for Individual Investors.

Current Price

0.92

Bid

0.00

Offer

0.00

Volume

-

0.00 Day's Range 0.00

0.71 52 Week Range 1.84

Market Cap

Previous Close

0.92

Open

-

Last Trade

Last Trade Time

Financial Volume

-

VWAP

-

Average Volume (3m)

2,361

Shares Outstanding

52,747,245

Dividend Yield

-

PE Ratio

-5.94

Earnings Per Share (EPS)

-0.16

Revenue

-

Net Profit

-8.17M

Elron Electronic Industries Ltd. is a leading Israeli holding company dedicated to building technology companies, primarily in the field of medical devices. Elron Electronic Industries Ltd. is a leading Israeli holding company dedicated to building technology companies, primarily in the field of medical devices.

Sector

Investors, Nec

Industry

Srch,det,nav,guid,aero Sys

Website

www.elron.com

Headquarters

Tel Aviv, Center, Isr

Founded

1962

Elron Ventures Ltd (CE) is listed in the Investors sector of the OTCMarkets with ticker ELRNF. The last closing price for Elron Ventures (CE) was US$0.92. Over the last year, Elron Ventures (CE) shares have traded in a share price range of US$ 0.71 to US$ 1.84.

Elron Ventures (CE) currently has 52,747,245 shares in issue. The market capitalisation of Elron Ventures (CE) is US$48.53 million. Elron Ventures (CE) has a price to earnings ratio (PE ratio) of -5.94.

Elron Electronic Industries to Present at 17th Annual Needham Growth Conference on Tuesday, January 13, 2015

Elron Electronic Industries to Present at 17th Annual Needham Growth Conference on Tuesday, January 13, 2015 PR Newswire TEL AVIV, Israel, Dec. 18, 2014 TEL AVIV, Israel, Dec. 18, 2014...

UPDATE: Roche Adds Diabetes Market Clout With Medingo Buy

Roche Holding AG (RHHBY) Tuesday said its diagnostics division will acquire Israel-based insulin pump maker Medingo Ltd for a total of up to $200 million, giving the Swiss pharma giant additional...

Roche To Buy Insulin Pump Producer Medingo For Up To $200 Million

Swiss pharmaceutical company Roche Holding AG (ROG.VX) said Tuesday it plans to acquire medical equipment company Medingo Ltd. for up to $200 million. MAIN FACTS: - Roche and Israel-based Elron...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	0	0	0.92	1.2582	0.92	3500	1.11325714	CS
4	0.04	4.54545454545	0.88	1.2582	0.85	2760	1.02013043	CS
12	-0.18	-16.3636363636	1.1	1.2582	0.71	2361	0.98549091	CS
26	-0.36	-28.125	1.28	1.28	0.71	3369	1.03243819	CS
52	-0.48	-34.2857142857	1.4	1.84	0.71	5671	1.33891903	CS
156	-2.88	-75.7894736842	3.8	3.8	1.0E-6	3094	1.72521789	CS
260	-0.7	-43.2098765432	1.62	4.5	1.0E-6	2965	2.14315379	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
NEPTFNeptune Wellness Solutions Inc (CE)	US$ 0.0238 (2,379,900.00%)	13.46k
CNVIFConavi Medical Corporation (PK)	US$ 0.58 (82,757.14%)	2.25k
FUNFFFansUnite Entertainment Inc (CE)	US$ 0.00055 (54,900.00%)	342.7k
RQHTFReliq Health Technologies Inc (CE)	US$ 0.0003 (29,900.00%)	219.11k
ELOXEloxx Pharmaceuticals Inc (CE)	US$ 0.0001 (9,900.00%)	1.53k
FDVXFFenixOro Gold Corporation (CE)	US$ 0.000001 (-100.00%)	10k
TMPOQTempo Automation Holdings Inc (CE)	US$ 0.000001 (-99.98%)	200
HLLPFHello Pal International Inc (CE)	US$ 0.000001 (-99.90%)	6k
MOTSMotus GI Holdings Inc (CE)	US$ 0.000001 (-99.88%)	649
BTAEFBeta Energy Corporation (CE)	US$ 0.000001 (-99.67%)	655
RSHNRushNet Inc (PK)	US$ 0.00015 (-25.00%)	502.31M
EARIEntertainment Arts Research Inc (PK)	US$ 0.0001 (0.00%)	428.38M
ASTAAstra Veda Corporation (PK)	US$ 0.0002 (-33.33%)	364.38M
RDARRaadr Inc (PK)	US$ 0.0009 (50.00%)	276.07M
CGACCode Green Apparel Corp (PK)	US$ 0.00065 (44.44%)	225.16M

tommydoyle.me2

tommydoyle.me2 9 minutes ago

Truthsocial

Truthsocial 26 minutes ago

Can someone who cares do a wellness check on sceeat...family members FDA or BIG Pharma please

Because RDGL and MAYO clinic are soon ready to move up in the outpatient cancer treatment world without sceeat....

The ELTP King

The ELTP King 28 minutes ago

This is my last post.

Taking a long break for the holidays.

Will return in early January.

Thanks.

Murphydog25

Murphydog25 28 minutes ago

Just gave Hitman a DM to talk about this stock going forward so I'm feeling more positive now after his positive words of wisdom 🤗
He also said he's doing well but finding 6 by 6 a small space and his flatmate ron'da snores 🧐

Azart

Azart 41 minutes ago

My friend what Scamus is currently doing is absolutely not new. This is exactly how everything was transferred from the previous company to becoming Rannever Health back in 2014 or 15 if I am not mistaken. The back then CEO before Scamus did the exact same thing Scamus is doing with Foxo. Common hol

SteveSchiets

SteveSchiets 46 minutes ago

There was a lot of resistance not acting up on my belief S7 hasn't play it's final hand. The fact that ACC's are used by our competitors made me do that silly thing. Maybe also because other stocks in my portfolio needs more time, i decided to have one last go (it's never the last). If trillions wi

knrorrel

knrorrel 1 hour ago

no chance in the quantum hype, $10 could come quickly now, like on Friday with qmco (+171%, only on Friday increased from $3.60 to $11!)

and it's a shame that they couldn't buy more,

but I feel the same way (I also have far too little of $QBTS but unfortunately I don'

chen1992

chen1992 2 hours ago

https://youtu.be/PaMsc8z1Ls4?si=u3MwvbGovNMyWXI6

Inverse Cramer at it again! Did it for TELL!!!!

silkmaster

silkmaster 2 hours ago

It looks like we can only guss what would the pps will look like in a week/month or a year from now .
Mean while lets play what would the PPS look like come 30/11/24 so long as KT will come out and talk to the public by than that is ...

A. 0.09 (around current pps)
B. 0.

ZLAZARUS

ZLAZARUS 2 hours ago

Ph3 melanoma data for IO102-IO103 remain on track for 1H25 and represents the next key catalyst. At .70 we are trading at cash. With a positive Ph3 melanoma readout we will be trading at $3.00 overnight with a march to $6.00 towards the later half of 2025. In addition, I'm encouraged by the support

knrorrel

knrorrel 2 hours ago

https://de.tradingview.com/chart/Mq3nUQ7Y/?symbol=NYSE%3AQBTS

knrorrel

knrorrel 2 hours ago

friday +171% / $11 and $Q_BTS follows on Monday, which is much better than QMCO and still has a lot of potential to trade above $10 ?
all only imho

here: https://investorshub.advfn.com/boards/read_msg.aspx?message_id=175432596

Whalatane

Whalatane 2 hours ago

Yes There will be less of a reaction in the UNCY stock for the reason you mentioned
ARDX is saying they will supply Xphozah free of charge to Medicare patients who lose coverage in Jan ...for the first 2 mths only
Nephrologists are probably already pulling back from starting Medicare

SCAMBUSTERKING

SCAMBUSTERKING 2 hours ago

My statements are backed up by the court docs filed by Jake and his lawyer... then even more proven by the actions of Jake.

chereb19

chereb19 2 hours ago

An even bigger Whopper of a lie. Can't believe anything you write, there's are too many examples of your lies. Dishonest and incompetent?

knrorrel

knrorrel 2 hours ago

THE $QBTS TREND https://stockcharts.com/sc3/ui/?s=QBTS

weedtrader420

weedtrader420 2 hours ago

☝️🤑☝️📈🚀

knrorrel

knrorrel 2 hours ago

THE $QBTS TREND https://stockcharts.com/sc3/ui/?s=QBTS

fuagf

fuagf 3 hours ago

And all should understand subsidies discourage innovation leading to efficiency.
You're right too, we are talking about corporate farming in that respect also.

Ray_137

Ray_137 3 hours ago

That can be true plan 7 contains some parts of plan6. Investors in WAMU signed releases based on plan7.

Kam8

Kam8 3 hours ago

I am guessing $2+ after approval in UK, not only 27cents.

dstock07734

dstock07734 3 hours ago

George,

It could be none of them.

Elron Ventures (CE)

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions